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Differences in antigenic sites and 
other functional regions between 
genotype A and G mumps virus 
surface proteins
Sigrid Gouma1,2,3, Tessa Vermeire4,5,6, Steven Van Gucht  4, Lennart Martens5,6, 
Veronik Hutse4, Jeroen Cremer1, Paul A. Rota7, Geert Leroux-Roels8, Marion Koopmans1,2, 
Rob van Binnendijk1 & Elien Vandermarliere5,6
The surface proteins of the mumps virus, the fusion protein (F) and haemagglutinin-neuraminidase 
(HN), are key factors in mumps pathogenesis and are important targets for the immune response during 
mumps virus infection. We compared the predicted amino acid sequences of the F and HN genes from 
Dutch mumps virus samples from the pre-vaccine era (1957–1982) with mumps virus genotype G strains 
(from 2004 onwards). Genotype G is the most frequently detected mumps genotype in recent outbreaks 
in vaccinated communities, especially in Western Europe, the USA and Japan. Amino acid differences 
between the Jeryl Lynn vaccine strains (genotype A) and genotype G strains were predominantly 
located in known B-cell epitopes and in N-linked glycosylation sites on the HN protein. There were 
eight variable amino acid positions specific to genotype A or genotype G sequences in five known 
B-cell epitopes of the HN protein. These differences may account for the reported antigenic differences 
between Jeryl Lynn and genotype G strains. We also found amino acid differences in and near sites on 
the HN protein that have been reported to play a role in mumps virus pathogenesis. These differences 
may contribute to the occurrence of genotype G outbreaks in vaccinated communities.
Mumps is a very contagious childhood disease that is caused by the mumps virus, a member of the 
Paramyxoviridae family. The infection generally affects the parotid glands, which leads to the most characteristic 
symptom, a unilateral or bilateral swelling of these salivary glands. The mumps virus can also cause inflamma-
tion of the testis, ovaries, pancreas or meninges and lead to complications such as infertility or deafness1,2. Since 
the introduction of the measles, mumps and rubella (MMR) vaccine in many national immunization programs, 
mumps incidence has dramatically decreased. However, in the last decade, several mumps outbreaks among vac-
cinated young adults have been reported3–7.
These recent outbreaks may be due to waning of vaccine-induced immunity over time. Waning immunity is 
the most likely hypothesis, because most of the outbreaks affected adolescents who received their last MMR dose 
more than 10 years before the outbreaks, and because (neutralizing) serum antibodies were still detected prior 
to mumps virus exposure8–13. Another possible contributing factor for these outbreaks is strain variation14–16. 
Antigenic differences between the currently circulating wild-type virus and the vaccine virus may reduce recogni-
tion by vaccine-induced antibodies. Mumps viruses are divided into multiple genotypes which are defined based 
on the nucleotide sequence of the small hydrophobic (SH) gene17. The most frequently used vaccine is the Jeryl 
Lynn vaccine which consists of a mixture of two mumps virus strains that both belong to genotype A, whereas the 
most frequently detected mumps genotype in recent outbreaks around the world with genotype information is 
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genotype G7,18–22. Although vaccine-induced antibodies neutralize genotype G strains, the level of neutralization 
is lower than for the vaccine strain (Rubin et al. 2008; Dayan & Rubin 2008; Gouma et al. 2016)12,23,24. This raises 
questions about the biological consequences of amino acid differences between genotype G and vaccine strains 
at sites that are important for immune recognition and pathogenesis. In addition, in silico analyses suggested 
differences in predicted B-cell and T-cell epitopes, but these studies did not focus on genotype G25,26. In this 
study, we compared the amino acid sequences from genotype A vaccine strains sequences and from genotype G. 
We focused on the fusion (F) and the haemagglutinin-neuraminidase (HN) proteins which are the main surface 
proteins of the mumps virus and are important for fusion, viral entry, and B-cell mediated antibody responses. 
All amino acid differences were also studied in the context of the protein structure. We found differences in 
known B-cell epitope regions and N-glycosylation sites, which could reduce immunological responses induced 
by the Jeryl Lynn vaccine. Additionally, differences were observed in regions that may play a role in mumps virus 
pathogenesis.
Results
Phylogenetic analysis. A phylogenetic analysis based on the SH gene sequences was performed to deter-
mine the genotypes of the samples from recent outbreaks in the Netherlands (n = 110), as previously described27, 
and from a collection of historic wild type strains isolated from Dutch patients since 1954 (n = 46) (Fig. 1). The 
strains from the recent outbreaks are classified as genotype G which is indeed the currently circulating genotype. 
Two historic wild type strains belong to genotype A, including a strain that is identical to MuVi/Boston.USA/0.45 
“Enders”, the mumps prototype strain that was isolated from a patient in the USA. These two strains were iso-
lated in 1954 and 1962, respectively. Three historic wild type strains belonging to genotype C were isolated from 
patients in 1980–1981. The majority of the historic wild type strains (n = 33) belong to genotype D and were 
isolated from patients (from 1961 to 1982), which indicates that this genotype circulated for several decades in 
the Netherlands before the introduction of the MMR vaccine. Four historic wild type strains belong to genotype 
L and were isolated from patients between 1957 and 1964. The four remaining historic wild type strains were 
isolated from patients between 1962 and 1964 and do not cluster with any of the genotypes as defined by the ref-
erence strains, which suggests a genotype that has not yet been described or may be extinct. Based on the SH gene 
sequences, these latter strains cluster together.
Analysis of the F protein. F protein amino acid sequences from genotypes A and G were compared at 
sequence level and additionally at structure level, by mapping sequence variation on homology models. The 
homology model of the F protein was built using PDB-entry 4GIP, which is the F protein of the parainfluenza 
5 virus (49% sequence identity). For the mapping of the sequence variation, Scop3D was used28, which is a tool 
designed to map sequence variation onto protein structure. Here, we used this tool to identify differences in resi-
dues on positions that are either specific to genotype A or genotype G strains. Because the F protein undergoes a 
large conformational change during the fusion process, it can adopt a pre- or post-fusion conformation29. In this 
work, we refer only to the pre-fusion conformation as this is the most important one for B-cell immunity.
Figure 1. Maximum parsimony tree based on SH gene sequences. Representation of classification of 46 mumps 
virus strains from the pre-vaccination era and 110 recent mumps virus strains, all indicated by thick lines. 
Percentages indicate bootstrap values (1000 replicates). All but one mumps virus strain were collected from 
Dutch patients, the non-Dutch strain was isolated from a patient from Albany, USA in 1954. Genotypes are 
labeled by color. Mumps virus sequences retrieved from GenBank (n = 78), including WHO reference strains 
(n = 27), are included in the phylogenetic tree and are indicated by thin lines.
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For the F protein, we found a total of 58 amino acid positions that show variation among the analyzed 
sequences of genotype A and G (Table 1). In a first analysis, only genotype A and G were compared. Only one 
position (position 2; Table 1, F row 1) is variable across both genotype A and genotype G sequences. Eight out of 
58 positions are completely different between the genotype A and G strains, i.e. all genotype A sequences have 
a certain residue at that position, whereas all genotype G sequences present another residue (Table 1, F row 2). 
Of these genotype-specific positions, five are located in the signal peptide (Table 2, Fig. 2) while the other three 
positions are not located in a predicted or defined functional region.
Four positions show a difference in a subset of the genotype A sequences when compared to genotype G 
(Table 1, F row 3). These four positions are not located in any specific functional region. Inversely, 10 positions 
were found to show a difference only in a subset of genotype G sequences, when compared to genotype A (Table 1, 
F row 4). Of these, two positions (positions 91 and 195) are linked to a fusion promotion site.
When the variable positions for each mumps virus strain were further compared with the historic wild type 
sequences also, four positions were found to be specific for both genotype A and genotype G (Table 1, F row 5 
and 6). Seven positions for genotype A were found to vary only within genotype A sequences (Table 1; F row 7). 
No positions are related to specific functional regions. When the same comparison was made for the genotype 
G sequences, 20 positions were found to be specific for the genotype G sequences in our study (Table 1, F row 
8). Four positions (positions 96, 97, 100 and 101) are related to the cleavage site (Table 1, Table 2, Figs 2, 3A). Of 
these four positions, the variation at position 97 (S → L) is observed in 19 out of 118 (16%) sequences (Figs 2, 3A). 
Furthermore, position 97 is surface exposed (56% solvent accessible; Fig. 2).
Analysis of the HN protein. The same approach was used to analyze the HN protein amino acid sequences. 
The homology model of the mumps HN protein is based on the HN protein of the parainfluenza 5 virus (PDB 
entry 1Z4V; 46% sequence identity). During the course of our analyses, the structure of HN from mumps was 
solved via X-ray crystallography (PDB entry 5B2C30). Our homology model used in the analyses was similar to 
this experimentally solved structure (root mean square deviation (RMSD) of Cα = 1.20 Å).
We found 54 positions that show a difference in the analyzed HN sequences of genotypes A and G. Four posi-
tions (288, 336, 462, 466) are variable across both genotype A and genotype G sequences (Table 1, HN row 1), 
of which positions 462 and 466 cluster together and occur two times within the same sequence (distance Cα - 
Cα = 4.8 Å). Position 466 (S → R) is located in an N-glycosylation site (464–466) and the variation leads to the 
loss of this N-glycosylation site. The S → R variant results in a major change in the physicochemical properties of 
the side chain. Position 336 is located in a known B-cell epitope region. In 14 positions, the genotype A and geno-
type G sequences differ completely (Table 1, HN row 2). One of these 14 positions is located in an N-glycosylation 
site (position 12 in N-glycosylation site 12–14; Table 2, Fig. 2). Five other positions are situated in two different 
known B-cell epitopes31 (B-cell epitopes 113–130 and 375–403, Table 2, Fig. 2). One position (287) is linked to a 
known T-cell epitope (region 265–295)25. Six of these 14 positions could be mapped on the structure. None of the 
positions cluster together. The variation at position 287 is surface exposed (rSAS = 39%; Fig. 2).
Additionally, seven and nine positions show variation in a number of genotype A or genotype G sequences, 
respectively (Table 1, HN rows 3 and 4). Of the seven variable positions for genotype A, position 464 is situated in 
an N-glycosylation site (464–466; Table 2, Fig. 2). For the nine positions variable in some genotype G sequences, 
two positions are located in an N-glycosylation site (positions 13 and 402 in N-glycosylation sites 12–14 and 
400–402, respectively; Table 2, Fig. 2). Four positions are located in five different known B-cell epitopes26,31–33 
(Table 1, HN row Table 2, Fig. 2).
When the comparison of the variable positions was also made against the historic wild type strains, three and 
two positions that differ completely between genotype A and G, are specific for either genotype A or G (Table 1, 
Variable positions F HN
Comparison between A 
and G only
shared between genotype A and 
genotype G sequences 2 288*, 336*, 462*, 466*
different between all genotype A and 
all genotype G sequences 3, 4*, 5*, 7*, 16*, 318*, 409, 454*
6, 9, 12, 21*, 56, 121, 122, 123, 287, 
372, 375, 399, 444*, 577
in subset of genotype A sequences 
only 70*, 95*, 477*, 489 44*, 81, 218, 279*, 464, 473*, 490*
in subset of genotype G sequences 
only
62, 69, 84, 91, 92*, 138*, 195*, 269, 
271, 498
13, 15, 25*, 130, 203, 353*, 402, 
474, 533
Comparison with 
genotype A or G and 
historic genotypes
genotype A specific 13, 49, 345, 480* 8*, 80, 356
genotype G specific 170, 330, 479, 488 113, 403
genotype A specific, but only in a 
subset of the sequences 11, 24*, 177, 275, 326*, 331, 431 135, 205, 214*, 354*, 442*, 470, 552
genotype G specific, but only in a 
subset of the sequences
14*, 96*, 97*, 100, 101, 115*, 141, 
209*, 273, 274, 280, 298, 317*, 350, 
389, 413, 425, 439*, 492, 530
37, 63, 94, 97*, 129*, 153, 317, 330
potentially located in B-cell epitopes none
113, 121, 122, 123, 129, 130, 203, 205, 
330, 336, 353, 354, 356, 375, 399, 402, 
403, 442, 533
Table 1. Variable positions found in the F and HN protein of genotype A and genotype G mumps virus 
sequences. Underlined positions are surface-exposed residues in the variable situation. *Non-conservative 
amino acid substitution.
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HN rows 5 and 6). The variations at positions 113 and 356 are surface exposed (rSAS = 40% and 54% respectively; 
Fig. 2). Position 113 is not surface exposed in the consensus situation (rSAS = 23%, Fig. 2). Three (positions 205, 
354 and 442) out of seven positions variable only in genotype A sequences, (Table 1; HN row 7) are located in 
known B-cell epitopes26,31–33 (epitope regions 199–207, 327–363 and 440–443). Eight positions are only variable 
in genotype G sequences when also compared to the historic wild type sequences, including positions 129 and 
330, which are located in known B-cell epitopes26,31–33 (Table 1, HN row 8, Fig. 2). These positions are also located 
in an N-glycosylation site (N-glycosylation sites 127–129 and 329–331). Only position 129 is surface exposed in 
the variable situation (rSAS = 30% versus 16%).
Taken together, of the 20 positions that are specific for either of the two genotypes, eight positions (positions 
113, 129, 205, 330, 354, 356, 403 and 442) are located in five different known B-cell epitopes26,31–33 (B-cell epitopes 
113–130, 199–207, 327–363, 375–403 and 440–443; Table 1, Table 2, Fig. 2)
Several variable positions clustered together when analyzed on the protein structure. Positions 336 and 399 
cluster together (distance Cα - Cα = 2.7 Å) and occur together in six sequences. Positions 354 and 356 also cluster 
together (distance Cα - Cα = 3.3 Å) and coexist in five sequences (Fig. 3B). Positions 464, 473 and 474 are located 
close to each other (distance Cα - Cα of 464 and 473 = 9.5 Å; distance Cα - Cα of 464 and 474 = 8.4 Å; distance Cα - 
Cα of 473 and 474 = 3.8 Å) and coexist in six sequences. Finally, positions 270 and 271 are positioned next to each 
other with concurrency in five sequences.
Discussion
In this study, we used the sequence variation between different mumps virus strains to assess whether this results 
in alterations in the structure of the mumps HN and F proteins that could contribute to the occurrence of the 
recent mumps outbreaks in vaccinated populations. Using homology models of the structure of the F and HN 
proteins, we compared the amino acid sequences of the genotype A vaccine strains with genotype G strains iso-
lated during recent outbreaks in The Netherlands. We included historic genotype strains as well as more ancient 
lineages of mumps viruses that had circulated in the Netherlands during the pre-vaccination era to check for 
genotype-specific variations only linked to either vaccine genotype A or genotype G mumps virus strains, which 
might explain new mumps outbreaks.
For the F protein, we found some variation, both for the genotype A and the genotype G strains. However, the 
positions that show variation were mostly located in regions not associated with known functional domains, or 
in regions with as yet unknown functional properties or were found only in a limited number of sequences. The 
variation found at position 97 in genotype G may be of interest, as this variant is located near the cleavage site 
of the F protein. The protease furin cleaves the F protein at this particular site, to expose the fusion peptide after 
some conformational changes during the fusion process. The exposure of the fusion peptide is essential for fusion 
of the virus with the host cell membrane29. The change at position 97 (S → L) might enhance the fusion process, 
by introducing more hydrophobicity in the environment of the fusion peptide.
In the HN protein, variation was mostly found in relation to known B-cell epitopes or N-glycosylation sites. 
The eight variable positions that are specific for one of the two genotypes and which are located in five known 
B-cell epitopes may have an effect on the ability of the antibodies, elicited by vaccination with the Jeryl Lynn vac-
cine, to recognize epitopes of genotype G viruses. This was also suggested previously by May et al., who showed 
that certain predicted epitope regions are divergent between the JL vaccine strain and wild type Dutch genotype G 
strains16. However, they only predicted possible B-cell epitopes, whereas we based the regions on literature, which 
Protein Region Residue positiona
F N-linked glycosylation pattern 73–75; 182–184; 352–354; 427–429; 433–435; 457–459
F Known B-cell epitope 221, 323, 373
F Fusion promotion 91; 195; 383
F Cleavage site 98–102
F Neurovirulence 91
HN N-linked glycosylation pattern 12–14; 127–129; 176–178; 284–286; 329–331; 400–402; 448–450; 464–466; 507–509; 514–516
HN Known B-cell epitope 113–130; 199–207; 220–240; 261–266; 327–363; 375–403; 440–443; 533
HN Known T-cell epitope 279; 287
HN Fusion promotion 82; 89; 96; 98; 102; 104; 111; 118; 222; 226; 228; 230; 567; 571
HN Receptor binding 162; 175; 226; 228; 230; 335; 407; 422; 530; 531; 533; 540; 566; 567; 575
HN Neuraminidase activity 180; 204; 239; 264; 268; 303; 407; 422; 466; 512; 540; 551; 561
HN Ca2+-binding 268; 270; 272; 302
HN Neurovirulence 360; 466
Table 2. Functional regions of the F and HN protein. aF protein numbering is based on accession number 
JN012242; HN protein numbering is based on accession number ABY81903. Regions and residue positions are 
based on references26,31,36,58–66.
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points to empirically proven epitopes. This results in the discrepancy that our study showed a possible relevant 
variation at positions 354 and 356. May et al. seemingly did not find these positions as variable. Additionally, 
according to our sources, these variations are located in a B-cell epitope, whereas May et al. did not predict this 
region as an antigenic site. Our study adds to this because we also examined the structures of both main surface 
proteins, as well as surface accessibility of the consensus and variable residues, in contrast to the study by May 
et al. where they only included secondary structure predictions. The structural information has an added value 
because the protein structures might reveal clustering of variable amino acids that are seemingly located distinctly 
from each other in the sequence, as seen for the HN protein, as well as to reveal clustering of functional regions 
of the protein. Clustering of variable positions, might have a cumulative impact on the protein structure and 
therefore antibody recognition. Additionally, we also analyzed more genotype G strains and compared variable 
positions to other mumps virus genotypes. This helped us to obtain a more general overview of the extent of 
variations throughout the genotype A or genotype G sequences as well as to define genotype-specific variations. 
The eight positions that we showed here to be variable and located in five known B-cell epitope regions should 
be further investigated. Although some positions displayed a conservative (i.e. similar physicochemical prop-
erties between amino acids) variation or were not surface-exposed, they may still have an effect on the tertiary 
structure. Positions 354 (Q → P), 356 (D → E) and 442 (S → Y) may be of special interest as these variations are 
specific for the genotype A sequences, both compared to genotype G as well as the other wild type sequences. 
Additionally, all three variants are surface exposed according to our analysis and the variation in positions 354 
and 442 is non-conservative (Fig. 3B). Also position 113 can be of interest because this variation is specific to 
genotype G sequences and is located in a known B-cell epitope. Positions 113, 354, 356 and 442 deserve further 
investigation because either all genotype A or genotype G sequences showed this variation unlike positions 129, 
205 and 330. These variable positions were found to be located in a B-cell epitope and/or an N-glycosylation 
site, which might change the recognition site for vaccine-induced antibodies, by loss of the N-glycosylation site 
(position 129). However, as this variation only appears in one sequence, it is most likely a random variant, and 
hence not genotype-specific. It is important to note that positions 113, 354, 356 and 442 are particularly inter-
esting as it was shown for other viruses such as influenza, that changes in as few as one amino acid located in a 
B-cell epitope can lead to reduced antibody recognition34. This observation can explain why a single amino acid 
change in a B-cell epitope can lead to the reduction or loss of recognition of this epitope by vaccine-induced anti-
bodies. Additionally, this hypothesis is supported by the finding that antibodies induced by the mumps vaccine 
(JL, genotype A) are less potent in neutralizing wild type virus than the vaccine virus (Rubin et al. 2008; Dayan & 
Figure 2. Overview of the consensus and the variable sequences of the F and HN proteins. Variation sequence 
shows all changes observed for both genotypes. Accessibility for the consensus (ACC consensus) and for the 
variation sequence (ACC variation), entropy and abundance are expressed as percentages and indicated by 
colors, indicated by the legend at the bottom. Epitope regions (italic, red) and glycosylation patterns (bold, blue) 
are indicated on the sequences. Parts of the structures that were missing in the protein models are indicated 
with the light blue regions. The upper part represents the F protein, the lower part the HN protein.
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Rubin 2008; Gouma et al. 2016)12,23,24. In our study, we found variation in eight positions located in five different 
B-cell epitopes. The four positions mentioned above (113, 354, 356 and 442) might be relevant and should be 
subject of further investigation to examine the influence of these variations on antibody recognition and viral 
neutralization.
We also found a small number of differences in or near other important functional regions of the HN protein. 
These variants are mostly conservative, which suggests that these positions do not tolerate much change most 
likely due to their primary function of virus-host cell fusion. For example, positions 203 and 205 in the HN pro-
tein changed from K to N and H to R in a small number of genotype G and genotype A sequences, respectively. 
These conservative variants are located near a neuraminidase region, which is an important functional region of 
the HN protein. In addition, we have not found any variable sites in regions important for Ca2+-binding, which 
plays a role in structural stability and these sites are therefore most likely conserved35.
Some of the variable positions found in this study were indeed empirically verified before. The variation found 
at position 354 in the HN protein, which is located in a known B-cell epitope, has also been described by other 
research groups26,36,37. Most of the variants found in the HN protein encompass the variable regions described 
in the study by Vaidya et al., in which they compared mumps virus genome sequences from two genotype G 
and six genotype C strains, with several vaccine strains, including the Jeryl Lynn strain38. Additionally, we show 
that these regions, except for regions 240–245 and 405–410, are surface exposed (Fig. 4). The antibody recogni-
tion of the protein surface might alter when certain residues become surface exposed or buried when variation 
Figure 3. Overview of important variable positions on both the HN and F protein, as described in the 
literature. (A) The F protein important functional regions with glycosylation sites (yellow), fusion promotion 
sites (orange), cleavage site (pink), neurovirulence (dark blue) and known B-cell epitope regions (green) 
mapped on the pre-fusion structure. Zoom is on the variation at position 97 (cyan blue) near the cleavage site 
(pink). (B) The HN protein with glycosylation sites (yellow), fusion promotion sites (orange), receptor-binding 
regions (pink), neuraminidase activity regions (cyan blue), Ca2+-binding sites (red), neurovirulence regions 
(dark blue), known T-cell epitope (purple) and known B-cell epitope regions (green) mapped on the structure. 
Zoom is on the variations at positions 354, 356 and 442 (brown positions).
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occurs, which might lead to loss of protection. We found variants at positions 279 and 287 (change of T to I and 
I to V, respectively) of the HN protein, which has also been reported previously25. This variation can generate a 
mismatch in recognition of CD4+ T-cell epitopes, between genotype A and genotype G strains. This may lead 
to the loss of an important T-cell response, which supports the immunological recognition and recall response. 
Positions 279 and 287 can both, individually and additively, lead to a difference in T-cell responses against the 
Jeryl Lynn vaccine strains and other wild type strains, as recognition of the T-cell epitope by the HLA molecules 
may be altered25. The study by Dilcher et al. showed that the above-mentioned interesting positions 279, 287, 336, 
356 and 442 indeed are related to known B-cell epitopes39. With their structural comparison they also concluded 
that differences between genotype A and genotype G mumps viruses might have an influence on antibody recog-
nition in these B-cell epitope regions.
In summary, despite the fact that the F and HN proteins of mumps viruses of genotype A and G are very 
similar, we have found a series of amino acid variations between these proteins of genotype A vaccine strains 
and genotype G wild type strains isolated from infected individuals. Most of the observed differences are located 
in regions of functional importance or in known B-cell epitopes. Therefore, it would also seem relevant to base 
mumps genotyping on the HN or F gene, instead of SH, as the differences in the HN or F gene are more relevant 
for the evolution of the virus, due to immunological pressure. It was shown previously that HN and F gene based 
genotyping is better suited for recording virus transmission27. The importance of appropriate genotyping was 
also recently shown by Dilcher et al., who reported a modified next generation sequencing protocol for better 
mumps diagnosis, variation analysis and outbreak control39. Eight variants specific for genotype A or G strains 
were located in five different known B-cell epitopes of the HN protein. These changes may lead to a reduced rec-
ognition of genotype G strains by vaccine-induced immune responses. This reduced recognition of B cell epitopes 
and the ensuing reduction of protective capacity of the vaccine-induced antibodies could thus contribute to the 
recent outbreaks of genotype G mumps in persons vaccinated with the genotype A JL vaccine. Functional assays 
are needed to corroborate our results and provide a conclusive answer to the question why mumps is resurgent 
in vaccinated populations.
Methods
Sequences. For this analysis, a total of 184 and 231 sequences were used for the F and HN protein, respec-
tively. Of the 184 sequences of the F protein, 28 sequences were retrieved from GenBank, i.e. 9 sequences of geno-
type A, 8 sequences of genotype G and 11 sequences of other genotypes (B, C, F, H and K; Supplementary Table 1). 
The remaining 156 sequences (46 pre-vaccine samples, 110 genotype G samples) were derived from patient sam-
ples collected at the RIVM. The 46 pre-vaccine samples were obtained between 1957 and 1982. Selection of the 
mumps virus strains was based on availability of the isolates. According to the available information for these iso-
lates, mumps virus had been cultured from oral swabs, nasal swabs and cerebral spinal fluid samples. All but one 
of the viruses were isolated from Dutch mumps patients. The non-Dutch isolate was from a patient from Albany, 
USA. These 46 sequences contained genotypes A, D, L and an unclassified genotype. The mumps virus genotype 
G sequences from 110 clinical samples obtained between 2004 and 2015 were also sequenced.
Similarly, 76 of the 232 sequences of the HN protein were retrieved from GenBank, i.e. 11 sequences 
of genotype A, 22 sequences of genotype G and 43 sequences of other genotypes (B, C, D, F, H, I, J, K and L; 
Supplementary Table 1). For each genotype at least one reference strain for that genotype was included17. The 
remaining 156 sequences were also derived from patient samples, as was done for the F protein, i.e. 46 sequences 
were pre-vaccine samples (genotype A, D, L and unclassified) and the other 110 sequences were genotype G 
sequences. For phylogenetic analysis, the SH gene sequences of 78 mumps virus strains were retrieved from 
Figure 4. In silico protein model of the F and HN protein with the specific functional regions mapped on the 
structures in different colors. (A) F protein with specific regions which are colored as described in the legend to 
Fig. 3. (B) HN protein with specific regions which are colored as described in the legend to Fig. 3.
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GenBank (Supplementary Table 1). The other 156 samples (46 pre-vaccine strains, 110 genotype G strains) 
were sequenced. The sequences of the 156 samples for the F, HN and SH proteins, have been described pre-
viously, except for one (Gouma et al. 2016). The GenBank accession numbers are: KJ125045-KJ125051, 
KJ125053-KJ125059, KJ125061-KJ125067, KU756625-KU756710, KU756712-KU756812, KU756814-KU756914, 
KU756916-KU756930, and KX136898-KX137038. As the Jeryl Lynn strain is a mixture of different strains, all 
sequences of the different Jeryl Lynn strains were included. In accordance with the Dutch law, no informed con-
sent was required for this study.
Sequencing and phylogenetic analysis. RNA extraction, cDNA synthesis and sequencing of the F 
gene, SH gene and HN gene for all genotype G mumps virus strains were performed as described previously 
(Gouma et al. 2016)12. For sequencing of the strains from the pre-vaccination era, the same procedures were 
followed for the sequencing of the F and SH gene for the genotype G strains, as previously described (Gouma 
et al. 2016)12. For sequencing of the HN gene, cDNA was synthesized with the use of primer FW-HN1 (nt 
6535–6555) and thereafter a PCR was performed with primers FW-HN1 and RV-HN1 (nt 8442–8460). The 
six primers used for sequencing were FW-HN2 (nt 6539–6557), FW-HN7172 (nt 7172–7191), RV-HN7233 
(nt 7212–7233), FW-HN7795 (nt 7795–7814), RV-HN7842 (nt 7823–7842) and RV-HN2 (nt 8435–8454) as 
described previously40. BioNumerics software version 7.5 (Applied Maths) was used to analyze nucleotide 
sequences and to recreate a maximum parsimony tree with bootstrap resampling (1000 replicates) based on the 
SH gene sequences.
Generation of the homology models. Homology models were generated for both the F and HN proteins, 
as there were no experimentally determined structures of the mumps F and HN proteins available, at the time of 
analysis. The consensus sequence was calculated for both the F and HN proteins based on 123 and 196 sequences, 
respectively, with the cons module of Emboss41. This consensus sequence was then used in a BLAST search42 
against the Protein Data Bank (PDB)43 to identify available structures of homologs for both proteins. Overall, 
PDB-entries 4GIP44 and 3MAW45 were used as templates for the F protein in the pre- and post-fusion conforma-
tion, respectively, as the F protein undergoes a conformational change during the fusion process29. PDB-entry 
4GIP44 contains the structure of the F protein from parainfluenza virus 5 and has an identity and similarity score 
with the mumps F protein consensus sequence of 49% and 69%, respectively; whereas PDB-entry 3MAW45 con-
tains the structure of the F protein from Newcastle Disease virus and has an identity and similarity score of 35% 
and 54%, respectively. PDB-entry 1Z4V46 was selected as template for the HN protein. This structure contains 
the HN protein from parainfluenza virus 5 and has an identity and similarity score with the mumps HN protein 
consensus sequence of 46% and 66%, respectively.
After selection of the templates, FoldX47 was used to replace the amino acids of the template with the mumps 
F and HN protein consensus sequences. Next, an energy minimization was carried out in YASARA with the 
YASARA force field48, to find the most stable local minimum of the protein conformation. Finally, the models 
were evaluated by MolProbity49, to avoid steric hindrance and side chain clashes.
For the F protein, positions 1–19, 101–102 and 478–538 are absent in the structure. For the HN protein, posi-
tions 1–79 and 119–127 are absent in the structure. These missing structures are signal peptides, located inside 
the virion, or are the transmembrane part of the protein.
Multiple sequence alignment and mapping of the mutations. Multiple sequence alignments for the 
F and HN protein sequences were performed with the aid of Muscle50,51. The sequence variation was subsequently 
mapped onto the protein structures with the aid of Scop3D, a tool to visualize variation across multiple sequences 
on the protein structure28. The entropy, which provides information on how random or specific the observed var-
iation is, was also calculated with Scop3D for both proteins. F protein numbering is based on GenBank accession 
number JN012242 and HN protein numbering is based on accession number ABY81903.
Determination and visualization of variable positions and specific functional regions. Specific 
functional regions were defined based on literature (Table 1). An N-glycosylation site is defined as the glycosyla-
tion recognition pattern N-X-S/T with X being any amino acid except P. All regions were subsequently mapped 
onto the sequences and models of the protein structures for analysis (Fig. 4), analyzed for diversity, and visual-
ized on the structures of the homology models with the aid of PyMol (PyMOL Version 11r1, Schrödinger LLC). 
Numbering of the positions is based on GenBank accession number JN012242 and GenBank accession number 
ABY81903, for the F and the HN protein respectively.
Calculation of the solvent-accessible surface area. The absolute solvent-accessible surface area 
(aSAS), the area of a residue that is accessible by a water molecule (radius of 1.4 Å), was calculated with the aid 
of DSSP52,53. The relative solvent-accessible surface (rSAS) area was then obtained by calculation of the ratio of 
the aSAS of the amino acid as present in the protein to the aSAS of the residue in the tripeptide G-X-G54,55. A 
residue is said to be surface-accessible (solvent exposed) if the relative SAS is >25%, otherwise a residue is said 
to be buried56,57. A surface exposed residue can be targeted by other molecules, such as antibodies. The RMSD 
of the homology model and the experimentally defined structure of the HN protein was calculated by using 
the Align command in PyMol (The PyMOL Molecular Graphics System, Version 1.1r1, Schrödinger, LLC).
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